---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-073304"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:41:16.684365+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q2 EPS $3.63 (+49% reported); raises FY2025 revenue and EPS guidance

## Summary
- Q2 revenue $1,109M (+11% reported, +9% organic); CAG Diagnostics recurring revenue +9% reported, +7% organic.
- Record quarterly instrument placements including nearly 2,400 IDEXX inVue Dx units.
- FY2025 revenue guidance raised to $4,205M-$4,280M (prior $4,095M-$4,210M); organic growth outlook 7.0%-9.0%.
- FY2025 EPS guidance raised to $12.40-$12.76 (prior $11.93-$12.43); reported growth 16%-20%.
- Operating margin guidance improved to 31.3%-31.6%; comparable expansion 50-80 bps.

## SEC filing metadata
- accession: 0001104659-25-073304
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000110465925073304/0001104659-25-073304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000110465925073304/tm2522386d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-073304
- JSON: https://secwatch.observer/filing/0001104659-25-073304.json
- Plain text: https://secwatch.observer/filing/0001104659-25-073304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.